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RESEARCH Open Access
Prevention of severe infectious
complications after colorectal surgery using
oral non-absorbable antimicrobial
prophylaxis: results of a multicenter
randomized placebo-controlled clinical trial
Tessa Mulder1 , Marjolein Kluytmans-van den Bergh1,2,3, Bart Vlaminckx4, Daphne Roos5, Anne Marie de Smet6,
Robert de Vos tot Nederveen Cappel7, Paul Verheijen8, Alexandra Brandt9, Anke Smits10, Eric van der Vorm11,
Erik Bathoorn12, Boudewijn van Etten13, Jacobien Veenemans14, Annemarie Weersink15, Margreet Vos16,
Nils van ’t Veer17, Stavros Nikolakopoulos1, Marc Bonten1,18 and Jan Kluytmans1,3*
Abstract
Background: Surgical site infections (SSIs) are common complications after colorectal surgery. Oral non-absorbable
antibiotic prophylaxis (OAP) can be administered preoperatively to reduce the risk of SSIs. Its efficacy without
simultaneous mechanical cleaning is unknown.
Methods: The Precaution trial was a double-blind, placebo-controlled randomized clinical trial conducted in six
Dutch hospitals. Adult patients who underwent elective colorectal surgery were randomized to receive either a
three-day course of preoperative OAP with tobramycin and colistin or placebo. The primary composite endpoint
was the incidence of deep SSI or mortality within 30 days after surgery. Secondary endpoints included both
infectious and non-infectious complications at 30 days and six months after surgery.
Results: The study was prematurely ended due to the loss of clinical equipoise. At that time, 39 patients had been
randomized to active OAP and 39 to placebo, which reflected 8.1% of the initially pursued sample size. Nine (11.5%)
patients developed the primary outcome, of whom four had been randomized to OAP (4/39; 10.3%) and five to
placebo (5/39; 12.8%). This corresponds to a risk ratio in the intention-to-treat analysis of 0.80 (95% confidence
interval (CI) 0.23–2.78). In the per-protocol analysis, the relative risk was 0.64 (95% CI 0.12–3.46).
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Conclusions: Observational data emerging during the study provided new evidence for the effectiveness of OAP
that changed both the clinical and medical ethical landscape for infection prevention in colorectal surgery. We
therefore consider it unethical to continue randomizing patients to placebo. We recommend the implementation
of OAP in clinical practice and continuing monitoring of infection rates and antibiotic susceptibilities.
Trial registration: The PreCaution trial is registered in the Netherlands Trial Register under NL5932 (previously:
NTR6113) as well as in the EudraCT register under 2015–005736-17.
Keywords: Infection control, Preoperative oral antibiotic prophylaxis, Colorectal surgery, Surgical site infection
Background
Surgical site infections (SSIs) are among the most
common healthcare-associated infections and affect
approximately 10 in every 100 patients who undergo
colorectal surgery [1, 2]. SSIs were associated with a sub-
stantial increase in morbidity [3] and mortality [4, 5],
prolongation of hospital stays [6, 7] and higher health-
care costs [8–11]. Despite the widespread adoption of
infection prevention measures aimed at reducing SSIs,
the risk remains high, which underlines the importance
of exploring additional precautions [2]. In the past, pre-
operative oral non-absorbable antibiotics were applied as
an infection control strategy for colorectal surgery. Be-
cause it was assumed that local antibiotics could only be
effective in an “empty” colon, simultaneous cleansing
was applied with osmotic fluids [12]. Routine use of this
cleansing, also referred to as mechanical bowel prepar-
ation (MBP), has recently become controversial due to
lack of evidence for advantageous effects. At the same
time, there are certain disadvantages, like the risk of de-
hydration, anastomotic leakage, or patient discomfort
[13, 14]. At the same time, the oral antibiotics, which
were often considered to be part of the MBP bundle,
were abandoned even though their efficacy without sim-
ultaneous MBP is unclear. Our study aimed to deter-
mine the efficacy of preoperative oral non-absorbable
antibiotic prophylaxis (OAP) without the routine admin-
istration of MBP on the risk of SSIs after elective colo-
rectal surgery.
Methods
An in-depth description of the rationale and methods
was published previously [15]. The trial is registered in
the Netherlands Trial Register under NL5932.
Trial design, participants and randomization
The study was designed as a double-blind placebo-
controlled randomized trial and was conducted from
April 2017 through August 2018 in six Dutch hospitals.
(Supplementary Table 1) Patients who were scheduled
for colorectal surgery and who had no absolute contra-
indication for the study medication [15] were eligible to
participate. Written informed consent was obtained
from all participants. Eligible patients were randomly
assigned in a 1:1 ratio to active OAP or placebo. The
randomization was performed by an independent
pharmacist, using a permuted block design with varying
block sizes and stratified per study center. The study’s
medication was packed in identical containers that were
sequentially numbered with unique numbers. The list
that linked these unique numbers to the treatment allo-
cation was securely kept at the coordinating pharmacy
(Amphia Hospital, Breda, the Netherlands). Everyone
who was involved in the study was blinded to the alloca-
tion until the end of the study.
Intervention
OAP was a solution of tobramycin (16 mg/mL) and co-
listin sulphate (20 mg/mL) that was taken four times
daily during the three days before surgery. Each dose
was 5 mL. Placebo had an identical color, smell, and
taste. The study medication was packed in bottles (100
mL) and distributed with 5 mL syringes. The bottles
were returned to the hospital after the intervention
period and were weighted to estimate treatment compli-
ance. All patients received perioperative intravenous
antibiotic prophylaxis according to the national guide-
lines [16].
Outcomes and safety reporting
Definitions of all outcomes are summarized in Fig. 1 and
were described in more detail in the trial protocol [15].
The primary outcome was deep SSI and/or mortality in
the 30 days after surgery. The CDC criteria were used to
diagnose SSIs [17]. Rectal carriage of HRE comprised
extended-spectrum beta-lactamase-producing Entero-
bacteriaceae (ESBL-E), and (non-intrinsic) carbapenem-
resistant, tobramycin-resistant and (non-intrinsic)
colistin-resistant Gram-negative Enterobacteriaceae.
HRE carriage was assessed by selective screening of rec-
tal swabs that were obtained at inclusion and 30 days
after surgery. EUCAST clinical breakpoints were used to
interpret MICs [18]. Cultures with a transport time of
more than 72 h were excluded from analyses as reliabil-
ity and quality could not be guaranteed. Quality of life
was assessed with the Rand-36 questionnaire [19]. This
Mulder et al. Antimicrobial Resistance and Infection Control            (2020) 9:84 Page 2 of 11
standardized questionnaire contains eleven questions to
assess the quality of life on nine different scales. The
scale scores range from 0 to 100%. Adverse events (AE)
related to the study medication were self-reported in a
medication diary. Other protocol related AE, Serious
Adverse Events (SAE), Serious Adverse Reactions
(SARs), and Suspected Unexpected Serious Adverse Re-
actions (SUSARs) were reported according to Good
Clinical Practice guidelines [20].
Study procedures and data collection
An overview of the study procedures is provided in
Supplementary Table 2. Demographic patient data, sur-
gery characteristics, and data on the primary and sec-
ondary endpoints were collected from the medical
records. Whole-genome sequencing was performed of




We assumed a 14.4% baseline incidence and a 40% rela-
tive reduction in the primary endpoint to calculate the
sample size. This was based on results from a before-
after study that was performed in a Dutch teaching hos-
pital where OAP was introduced as a standard of care
before elective colorectal surgery [21]. With a one-sided
alpha of 2.5%, power of 80%, and one interim analysis,
the final sample size resulted in 966 patients.
Data analysis
Data were analyzed according to the intention-to-treat
principle. We calculated crude risks for every outcome
and a corresponding risk ratio (RR) and 95% confidence
interval (CI) to compare the risks in the intervention arm
with the placebo arm. A per-protocol analysis was per-
formed in the 100% compliant population. Continuous
outcomes were analyzed using Student’s t-test or Mann
Whitney U-test, as appropriate. Quality of life after six
months was corrected for the baseline scores by calculat-
ing the change (delta) in scores. Negative deltas reflect a
worse perception of quality of life compared to baseline,
whereas positive values reflect improvement. We evalu-
ated whether our study population was a representative
sample of the patient population by comparing average
baseline characteristics with surveillance data from a
Dutch hospital that did not participate in the study. Statis-
tical analyses were performed using R version 3.3.2.
Results
Patient enrollment is shown in Fig. 2. The number of
participants and the inclusion period per hospital are
Fig. 1 Definitions of primary and secondary endpoints. SSIs were diagnosed with the CDC criteria [17]. CDC, Centers for Disease Control and
Infection Prevention; ESBL-E, extended spectrum beta-lactamase producing Enterobacteriaceae; ICU, intensive care unit; SSI, surgical site infection
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presented in Supplementary Table 3. The trial ended
after 18 months when 78 participants (8.1% of the sam-
ple size) had been enrolled. All patients completed the
intervention period. During the six-month follow-up
period, one person was lost to follow-up and four dis-
continued active participation but gave consent to con-
tinue data collection from their medical records.
The baseline characteristics of the participants are
shown in Table 1. Thirty-nine patients were included in
each treatment arm. The median age was 68 years, and
68% of patients were male. Colorectal malignancies were
the indication for surgery in all except one of the pa-
tients (98.7%). Even though it was not part of routine
care, MBP was applied in 3.8% of the patients. Based on
the leftovers of study medication that were returned, we
estimated that 57.7% of the patients took all twelve doses
of study treatment.
The effect of OAP on primary and secondary out-
comes is presented in Table 2. In total, nine (11.5%) pa-
tients developed outcome deep surgical site infection; all
survived. Four received OAP (4/39; 10.3%) and five pla-
cebo (5/39; 12.8%). This corresponds to a risk ratio in
the intention to treat analysis of 0.80 (95% CI [0.23–
2.78]). There was no statistical difference between the
treatment arms for any of the outcomes, except for a dif-
ference in the quality of life after six months that was
improved compared to baseline on most scales in pa-
tients who had received OAP, and worsened in patients
who had received placebo. In the per-protocol analysis,
the risk ratio for the primary outcome was 0.64 (95% CI
0.12–3.46). The predictive power for the planned sample
size given the observed results (that is, the probability of
having a significant result at the end of the study, was
for it to be completed, given the observed results in the
78 patients) was 67%. Due to insufficient power, we were
unable to perform any of the preplanned subgroup ana-
lyses [15].
We collected 66 valid baseline rectal swabs and 62
valid follow-up rectal swabs (Table 3). There is no differ-
ence between the carriage of antibiotic-resistant micro-
organisms between the two treatment arms at baseline
or 30 days after surgery. In colistin-resistant isolates, no
acquired colistin resistance genes were found. The car-
riage of tobramycin resistant species was approximately
Fig. 2 CONSORT flowchart of enrolment of participants. Logistical issues were unexpected changes in the date of surgery that led to insufficient
time to complete the three-day intervention period (n = 1) or missed appointments for the informed consent procedure due last-minute changes
in the outpatient clinic schedule (n = 3)
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40% both at baseline and 30 days after surgery, which
was due to acquired tobramycin resistance genes in 9%
of the cultures at baseline and 19.4% 30 days after
surgery.
Of the eleven SSI that developed, three were con-
firmed with a microbiological culture, of which two were
performed on abdominal pus collected during reopera-
tion and one directly on the incision. (Supplementary





Age in years 67 (61–72) 69 (61–73)
Male sex 28/39 (71.8) 25/39 (64.1)
ASA classification ≤2 26/38 (68.4) 30/36 (83.3)
Charlson Comorbidity Index
1–2 22/39 (56.4) 25/39 (64.1)
3–4 9/39 (23.1) 2/39 (5.2)
≥ 5 8/39 (20.5) 12/39 (30.1)
Immunosuppressive therapy a 0/39 (0.0) 2/39 (5.2)
BMI in kg/m3, median (IQR) 28 (24–31) 26 (23–29)
Obese (BMI > 30) 9/39 (23.1) 5/38 (13.2)
Abdominal surgery in the previous year 1/39 (2.3) 2/39 (5.2)
Oral mechanical bowel preparation 1/39 (2.3) 2/39 (5.2)
Indication for surgery
Colorectal malignancy 38/39 (97.4) 39/39 (100)
Inflammatory bowel disease 1/39 (2.3) 0/39 (0.0)
Wound class
Clean-contaminated (class 2) 37/39 (94.9) 39/39 (100)
Contaminated (class 3) 2/39 (5.1) 0/39 (0.0)
Type of resection
Right sided hemicolectomy 13/39 (33.3) 9/39 (23.1)
Left sided hemicolectomy 2/39 (5.2) 4/39 (10.3)
Sigmoid resection 10/39 (25.6) 8/39 (20.5)
Low anterior resection or rectum amputation 10/39 (25.6) 15/39 (38.5)
(Sub) total colectomy 2/39 (5.2) 0/39 (0.0)
Other 2/39 (5.2) 3/39 (7.7)
Surgical approach
Laparotomy 4/39 (10.3) 4/39 (10.3)
Laparoscopy b 28/39 (72.0) 26/39 (66.7)
Robotic laparoscopy 7/39 (17.8) 9/39 (23.1)
Duration of surgery in minutes, median (IQR) 148 (117–185) 150 (116–215)
Duration >75th percentile c 8/38 (21.1) 13/37 (35.1)
Normothermia after procedure 22/28 (78.6) 25/31 (80.1)
Stoma 6/38 (15.8) 14/39 (35.9)
Perioperative intravenous antibiotic prophylaxis 37/39 (94.9) 37/38 (97.3)
Complete compliance to study medication (all 12 doses) 23/33 (69.7) 22/33 (66.7)
Data are presented as n/N with data (%), unless specified otherwise. ASA, American Society of Anesthesiologists; BMI, body mass index; IQR, interquartile range;
OAP, oral antibiotic prophylaxis
a Because of chemotherapy
b Of which 6 (15.4%) were converted to open procedures in OAP arm and 1 (2.3%) in placebo arm
c 75th percentiles of duration of surgery, based on type of resection and approach [22]
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Table 4). None of the pathogens cultured were resistant
to tobramycin or colistin.
Adverse events during the intervention period are pre-
sented in Table 4. Out of the 65 (83.3%) patients who
returned their medication diary, 56 (86.2%) patients took
at least one dose of study medication. Of those, 24
(42.9%) did not report any side effects. The most adverse
events were gastrointestinal side effects. Patients who re-
ceived OAP more often reported diarrhea compared to
those who received a placebo (51.9% versus 20.7%) as
well as nausea (11.1% versus none). During the study,
there was one SAE, which was a transient ischemic at-
tack that occurred before the start of the intervention
phase. No other adverse events related to either study
medication or other study procedures were reported.
To estimate whether our cohort was a representa-
tive sample of the patient population, we compared
the baseline characteristics with a comparison cohort
of 1597 patients. (Supplementary Table 5) Compared
to the comparison cohort, the patients in the trial co-
hort were more often men, (67.9% versus 55.5%), had
more colorectal malignancies (98.7% versus 74.5%),
more minimally invasive procedures, but less abdom-
inal surgery in the preceding year (3.8% versus
12.0%). The quality of life indicators, as shown in
Table 2, all showed a more positive trend in the OAP
Table 2 Intention-to-treat analysis of OAP on the risk on primary and secondary outcomes
OAP Placebo
n/N (%) RR (95% CI)
Deep SSI and/or mortality 4/39 (10.3) 5/39 (12.8) 0.80 (0.23–2.78)
Deep SSI 4/39 (10.3) 5/39 (12.8) 0.80 (0.23–2.78)
30-day mortality 0/39 (0.0) 0/39 (0.0) N/A
Superficial SSI 1/39 (2.6) 1/39 (2.6) 1.00 (0.06–15.40)
Anastomotic leakage 1/39 (2.6) 2/39 (5.2) 0.50 (0.05–5.29)
Re-operation 3/39 (7.9) 2/39 (5.3) 1.50 (0.27–8.49)
Bacteremia 0/39 (0.0) 0/39 (0.0) N/A
Infection with HRE 0/39 (0.0) 0/39 (0.0) N/A
Infection with Clostridium difficile 0/39 (0.0) 0/39 (0.0) N/A
6-month mortality 0/39 (0.0) 0/39 (0.0) N/A
Median (IQR) P value
In-hospital use of antibiotics, DOTa 0.0 (0.0–0.0) 0.0 (0.0–4.0) 1.000
Length of stay, daysb 7.0 (5.0–13.0) 6.0 (5.0–12.0) 0.497
Length of ICU stay, daysb 4.0 c 0 N/A
Median delta (IQR) P value
Quality of lifed
Physical functioning −5.0 (−15.0–5.0) −10.0 (−20.0–5.0) 0.124
Social role functioning 0.0 (0.0–12.5) −12.5 (−25.0–0.0) 0.007
Physical role functioning 0.0 (0.0–25.0) −12.5 (−93.7–0.0) 0.007
Emotional role functioning 0.0 (0.0–0.0) 0.0 (−25.0–0.0) 0.237
Mental health 4.0 (−1.0–13.0) 0.0 (−7.0–8.0) 0.072
Vitality 5.0 (−5.0–10.0) −10.0 (−20.0–0.0) 0.002
Pain 0.0(−10.2–10.7) −11.2 (−23.0–6.1) 0.002
General health perception 7.5 (0.0–15.0) −5.0 (− 15.0–3.75) 0.014
Change in health 0.0 (0.0–50.0) 0.0 (−25.0–0.0) 0.092
Length of (ICU) stay, quality of life and 6-month mortality were assessed 6months after surgery, all other outcomes were evaluated 30 days after surgery. DOT,
days on therapy; HRE, highly resistant Enterobacteriaceae; ICU, intensive care unit; IQR, interquartile range; N/A, not available; OAP, oral antibiotic prophylaxis; RR,
risk ratio; sd, standard deviation; SSI, surgical site infections
a9 patients in the OAP arm and 10 patients in the placebo arm were treated with antibiotics
bIncluding all readmissions within 6months
cOnly 1 patient was admitted to the ICU
dDelta was calculated by subtracting baseline scores from scores at 6-month follow-up. Negative delta’s reflect worse perception of quality of life on compared to
baseline. Number of completed follow-up questionnaires: 27 (69.2%) OAP, 32 (82.1%) placebo
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Table 3 Rectal carriage of (non-intrinsic) antibiotic resistant microorganisms
Patients, n/N (%)
OAP Placebo P value
Baseline
Number of valid rectal cultures 35/39 (89.7) 31/39 (79.5)
Rectal carriage of HRE
ESBL-E 2/35 (5.7) 1/31 (3.2) 1.000
Carbapenem-resistant Gram-negative bacteria 1/35 (2.9) 2/31 (6.5) 0.597
Carbapenemase-gene present 1/35 (2.9) 2/31 (6.5) 0.597
Tobramycin-resistant Gram-negative bacteria 12/35 (34.3) 14/31 (45.2) 0.452
Acquired aminoglycoside resistance gene present 1/35 (2.8) 5/31 (16.1) 0.088
Colistin-resistant Gram-negative bacteria 7/35 (20.0) 6/31 (19.4) 1.000
Acquired colistin resistance gene present 0/35 (0.0) 0/31 (0/0) 0
30 days after surgery
Number of valid rectal cultures 34/36 (94.4) 28/35 (80.0)
Rectal carriage of HRE
ESBL-E 1/34 (2.9) 1/28 (3.6) 1.000
Carbapenem-resistant Gram-negative bacteria 0/34 (0.0) 1/28 (3.6) 0.452
Carbapenemase gene present 0/34 (0.0) 1/28 (3.6) 0.452
Tobramycin-resistant Gram-negative bacteria 15/34 (44.1) 10/28 (35.7) 0.606
Acquired aminoglycoside resistance gene present 7/34 (2.1) 5/28 (17.9) 0.318
Colistin-resistant Gram-negative bacteria 4/34 (11.9) 4/28 (14.3) 0.320
Acquired colistin resistance gene present 0/34 (0.0) 0/28 (0.0) 1.000
Data are presented as n/N (%). P values are estimated using Fisher’s exact test. ESBL-E, Extended-Spectrum Beta Lactamase-producing Enterobacteriaceae; OAP,
oral antibiotic prophylaxis
Table 4 Adverse events
Patients, n/N (%)
OAP Placebo P value
Adverse events related to study medication
Self-reported side effects during intervention perioda
No side effects 13/27 (48.1) 11/29 (37.9) 0.596
Gastro-intestinal side effects
Diarrhea 14/27 (51.9) 6/29 (20.7) 0.015
Nausea 3/27 (11.1) 0/29 0.065
Stomach ache 7/27 (25.9) 6/29 (20.7) 0.624
Loss of appetite 1/27 (3.7) 0/29 0.296
Flatulence 1/27 (3.7) 3/29 (10.3) 0.335
Other side effects 5/27 (18.5) 4/29 0.630
Serious adverse reaction (SAR) 0/39 (0.0) 0/39 (0.0) 0
Serious unexpected suspected adverse reaction (SUSAR) 0/39 (0.0) 0/39 (0.0) 0
Adverse events related to other study procedures 0/39 (0.0) 0/39 (0.0) 0
Serious adverse event (SAE) 1/39 (2.6) 0/39 (0.0) 1.000
Data are presented as n/N with data. Denominators for the self-reported side effects are based on the number of medication diaries that were returned: OAP 32/
39 (82.1%), placebo 33/39 (84.6%). OAP, oral antibiotic prophylaxis
aSelf-reported in medication diary during the three days of administration of study medication, including all participants who took at least one dose of
study medication
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group with a significant difference for social, physical,
and emotional role functioning.
Discussion
Due to the premature termination of this multicenter,
double-blind, placebo-controlled randomized clinical
trial, we were unable to determine the efficacy of OAP
in terms of the risk of SSI and other postoperative
complications.
The use of oral antibiotic prophylaxis in colorectal
surgery is a controversial topic. Several studies demon-
strated a reduced risk of SSI when OAP was adminis-
tered before surgery [23, 24]. However, the question of
whether preoperative oral antibiotic prophylaxis is ef-
fective without MBP remains unanswered as all RCTs
published to date combine OAP with MBP. The best
available evidence on OAP efficacy is provided by a re-
cent network meta-analysis that aimed to study the best
strategy for bowel preparation. This study also empha-
sized the knowledge gap on OAP without MBP, as the
absence of RCTs that included this strategy as a treat-
ment arm forced the authors to estimate the efficacy of
OAP based on indirect comparisons only. Though based
on indirect comparisons, a significant reduction in
organ/space SSIs was found with OAP only, compared
to no preparation (OR 0.13 [95% CrI 0.02–0.55]). This
strategy was superior to combining OAP with MBP.
Data on the effectiveness of OAP without simultan-
eous MBP is also provided by several retrospective ob-
servational studies that compared the different bowel
preparation strategies. These studies reported conflicting
results on effectiveness [25–36]. Potential confounding
by indication and limited numbers of patients treated
with only OAP hamper concluding on the effectiveness
of OAP in the absence of MBP and exemplifies the need
for well-controlled and adequately powered studies.
We consider the randomized design as a major
strength of our study, which facilitated the unbiased as-
sessment of the efficacy of OAP and its potential drug-
related side effects. Although the quality of our design is
high, selective participation could not be prevented en-
tirely. Unfortunately, not all potential participants were
screened. Patients suffering from multiple or more se-
vere comorbidities were not always considered for par-
ticipation even though they were eligible. This might
have had an impact on the generalizability of the study
population. Also, multiple other studies were being con-
ducted within this patient population, which competed
with our inclusions. Baseline characteristics of our co-
hort showed potentially relevant differences with those
from a historical cohort of patients undergoing colorec-
tal surgery from a different hospital. There are indica-
tions that the patients that we included differed from the
source population. For example, the percentage of
patients with colorectal malignancy in our cohort was
higher. A recently implemented national screening pro-
gram for colorectal cancer led to the detection of malig-
nancies in an earlier stage. In general, these patients are
in a better clinical condition, and surgery is less radical,
which lowers the risk of SSI.
Treatment with OAP was associated with a significant
improvement in perception of quality of life at six
months after surgery. At the same time, worsening was
seen for patients treated with a placebo. In the absence
of an effect of OAP on any of the clinical outcomes that
could have been a possible explanation for this improve-
ment, we suggest further investigation to study whether
and how OAP might impact the quality of life.
Because of the small sample size, we were unable to
study the safety of OAP thoroughly. However, several
patients who received OAP reported mild gastrointes-
tinal side effects and an unappealing taste. When OAP is
considered for implementation in the future, patients
should be informed about these potential side effects
and the necessity of completing the entire three-day
course of OAP despite these side effects. Another im-
portant safety concern is the risk of developing antibiotic
resistance. We found the prevalence of colistin and
tobramycin resistance at baseline to be 16.7 and 39.4%,
respectively. The prevalence of carriage of tobramycin
and colistin-resistant species did not increase in both
treatment arms. We compared our findings with the re-
sults obtained with the implementation of selective de-
contamination of the digestive tract (SDD), a
comparable antibiotic prophylaxis containing tobra-
mycin, colistin, and nystatin that is used in several
Dutch ICUs. In a post hoc analysis of two multicenter
trials, it was shown that during SDD use, the prevalence
of colistin resistance ranged from 1.7 to 2.8%, and of
tobramycin resistance from 6.2 to 8.0%, respectively [37].
Other studies on SDD found a comparable prevalence
[38–40]. The selective culture methods that we used in
our study are known to have a higher sensitivity to de-
tect antimicrobial-resistant Gram-negative bacteria [41],
and may explain the higher prevalence observed com-
pared to other studies. Due to the small number of pa-
tients, we were unable to exclude that OAP may
increase the risk of developing antibiotic resistance.
Ethical considerations
At the time this trial was initiated, there was no consen-
sus within the Dutch surgical community on whether
OAP should be used before colorectal surgery and, as a
result, it was not part of clinical care in the vast majority
of hospitals. Because of the uncertainty about the effi-
cacy of the intervention, there was clinical equipoise re-
garding the use of OAP [42]. The shift started when the
findings of a single-center before-after study were
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published. This before-after study was performed in the
same setting without routine MBP administration [21].
In contrast to previous observational studies, the risk of
confounding by indication was minimized because OAP
was implemented as the standard of care and prescribed
to all patients who underwent elective colorectal surgery.
After implementation, a 42% reduction was observed in
the risk of SSI and mortality within 30 days after surgery
(aRR 0.58 [95% CI 0.40–0.79)]. Due to the single-center
aspect of the study and the risk of residual confounding,
a well-controlled study was deemed necessary to confirm
the treatment effect.
We faced multiple problems recruiting participants
throughout the entire study period despite our efforts to
improve the inclusion rate. The unexpectedly low re-
cruitment rate was communicated with the participating
hospitals. Supported by the effectiveness found in the
observational study, several investigators considered
awaiting the trial results unacceptable and decided to
implement OAP to reduce SSI rates. We decided to end
the trial prematurely, because the assumption of clinical
equipoise regarding the administration of OAP was no
longer valid, and the use of a placebo was no longer eth-
ically justifiable.
To conclude, we could not evaluate the efficacy of
OAP on SSI risk and other postoperative complications
after colorectal surgery due to premature termination of
this double-blind, placebo-controlled, randomized clin-
ical trial. Due to the loss of clinical equipoise, we will no
longer consider the use of placebo in clinical trials on
the efficacy of OAP ethics. Considering the current evi-
dence, we recommend the implementation of OAP in
clinical practice and the continued monitoring of infec-
tion rates and antimicrobial resistance.
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